Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.6153 +0.0177 (+2.96%)
Delayed Quote Updated: 2:25 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Top U.S. Gainers and Losers for Oct. 27, 2026 Session ↗
Via Chartmill
Top Market Movers: US Gainers and Losers for October 27, 2026 ↗
Via Chartmill
Gap-Up and Gap-Down Stocks in Today's Session ↗
Via Chartmill
Premarket Movers: Gainers and Losers Ahead of Today's US Open ↗
Via Chartmill
After-Hours Movers: SNTI, BRAI, CLS Rise; SPRC, DVLT Fall ↗
Via Chartmill
US Session Top Percentage Movers: Gainers and Losers Among Small-Cap Stocks ↗
Via Chartmill
Gap Stock Movers: SGRY Leads Gap-Ups and XP Leads Gap-Downs in Today's Session ↗
Via Chartmill
Premarket Movers: Gainers and Losers Ahead of Today's US Session ↗
Via Chartmill
News headline image
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
From SciSparc Ltd
Via GlobeNewswire
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing... 
Via TheNewswire.com
News headline image
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
From SciSparc Ltd
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
News headline image
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq:... 
Via TheNewswire.com
News headline image
Neurothera Labs Inc. Announces Share Consolidation
Toronto, Ontario – August 28, 2026 –– TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC),... 
Via TheNewswire.com
News headline image
NeuroThera Labs Engages Dr. Reuter Investor Relations
Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC),... 
Via TheNewswire.com
News headline image
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
From SciSparc Ltd
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 million. SciSparc (NASDAQ:SPRC)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.